Processing...
Clinical Trials for Prostate Cancer
Search
Search
There are 213 active trials for advanced/metastatic prostate cancer.
Click on a trial to see more information.
213 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with metastatic castration-resistant prostate adenocarcinoma after ≥2 prior lines (including a next-generation AR inhibitor) and castrate testosterone receive lymphodepleting cyclophosphamide/fludarabine followed by a single infusion of autologous STEAP1-directed CAR T cells plus continuous enzalutamide. The investigational product is a CAR T therapy targeting STEAP1 to direct T‑cell cytotoxicity against STEAP1-expressing tumors; key exclusions include active autoimmune disease requiring immunosuppression, uncontrolled infection, and untreated/symptomatic brain metastases.
ClinicalTrials.gov ID: NCT06236139
TrialFetch AI summary: Adults with advanced/metastatic solid tumors refractory to standard therapy (mCRPC, metastatic breast cancer subtypes including TNBC, HR+/HER2− or HER2-low, HR−/HER2+, NSCLC, CRC, PDAC) receive MBRC-201, an investigational antibody‑drug conjugate targeting a tumor-associated antigen and delivering a likely topoisomerase I inhibitor payload. Requires ECOG 0–2 and measurable disease in expansion/Phase 2; excludes active CNS disease and prior camptothecin‑payload ADCs in later phases.
ClinicalTrials.gov ID: NCT07145255
TrialFetch AI summary: Adults with PSMA-avid metastatic castration-resistant prostate adenocarcinoma and bone marrow involvement causing baseline anemia (Hgb 7 to <9 g/dL or recent pretransfusion <8) and/or thrombocytopenia (platelets 50–100 × 10^9/L), with PSA progression after at least one prior approved systemic therapy (while continuing ADT) and ECOG 0–2. All patients receive 177Lu-PSMA-617, a PSMA-targeted radioligand delivering lutetium-177 beta radiation to PSMA-expressing tumor cells, with primary focus on hematologic safety/tolerability in this cytopenic population.
ClinicalTrials.gov ID: NCT07025512
TrialFetch AI summary: Enrolling adult men with progressive metastatic castration-resistant prostate adenocarcinoma (ECOG 0–1) on continuous ADT with castrate testosterone, including bone-only disease, with no prior 177Lu-PSMA-617 or sipuleucel-T. Participants are randomized to PSMA-targeted radioligand therapy 177Lu-PSMA-617 (beta-emitting lutetium-177 delivering radiation to PSMA-expressing cells) IV every 6 weeks for up to 6 cycles versus the same regimen plus sipuleucel-T (autologous PAP–GM-CSF–activated cellular immunotherapy) given every 2 weeks for 3 doses starting around week 8.
ClinicalTrials.gov ID: NCT07219147
TrialFetch AI summary: This trial involves patients with advanced or metastatic solid tumors expressing Nectin-4, including urothelial carcinoma, triple-negative breast cancer, non-small cell lung cancer, and ovarian cancer, who have exhausted standard therapy options. It evaluates LY4052031, an antibody-drug conjugate that targets Nectin-4 to deliver a topoisomerase I inhibitor, aiming to assess its safety, tolerability, and efficacy in these patients.
ClinicalTrials.gov ID: NCT06465069
TrialFetch AI summary: This trial enrolls patients aged 18 and older with advanced solid tumors, including RCC, CRPC, NSCLC, SCCHN, CRC, endometrial, and ovarian cancers, who have failed or are ineligible for standard treatments, to evaluate TT-10, an adenosine A2A receptor antagonist, and TT-4, an adenosine A2B receptor antagonist, administered as single agents and in combination.
ClinicalTrials.gov ID: NCT04969315
TrialFetch AI summary: Eligible patients are adults with advanced or metastatic solid tumors—including urothelial, triple negative breast, non-small cell lung, esophageal, pancreatic, ovarian, cervical (squamous), head and neck squamous cell, and prostate cancers—who have exhausted standard therapies and have ECOG 0–1. All participants receive intravenous LY4101174, a novel antibody-drug conjugate targeting nectin-4 and delivering a topoisomerase I inhibitor (exatecan).
ClinicalTrials.gov ID: NCT06238479
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic ER+ HER2- breast cancer, mCRPC, or NSCLC who have progressed after standard therapies, to receive OP-3136, an oral selective KAT6A/B inhibitor targeting key epigenetic regulators, as monotherapy. Eligible patients must have unresectable disease or no further effective standard treatment options.
ClinicalTrials.gov ID: NCT06784193
TrialFetch AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors—including a wide range such as head and neck, lung, bladder, prostate, breast, colorectal, and others—who have progressed on or are intolerant to standard therapies. Patients receive MGC026, a B7-H3-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor (exatecan), with cohorts in both dose escalation and expansion phases.
ClinicalTrials.gov ID: NCT06242470
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors who have progressed after standard therapies to receive DB-1310, a HER3-targeting antibody-drug conjugate with a topoisomerase I inhibitor payload, as monotherapy or in combination with trastuzumab (HER2+ breast cancer) or osimertinib (EGFR-mutant NSCLC). Key eligibility includes measurable disease, ECOG 0-1, and no prior HER3-ADC or topoisomerase I inhibitor exposure.
ClinicalTrials.gov ID: NCT05785741